New Delhi: Sir Ganga Ram Hospital has commenced administration of Monoclonal Antibody Cocktail (MAC) from 01 June 2021, a combination of Casirivimab & Imdevimab to consenting patients with mild & moderate Covid-19 symptoms at high risk of developing serious illness.
As per Drug Controller General of India (DCGI), selection of patients will entail that they:
(A) have Covid-19 Positive test report.
(B) have mild to moderate Covid disease.
(C) are in the age group of 12 & above and weighing at least 40Kg.
(D) are at high risk of Covid-19.
The MRP of one MAC dose for a patient will be Rs. 59,750/- only.
Dr. D.S. Rana, Chairman (BOM), Sir Ganga Ram Hospital said, “As per the claims of the company Roche/ Cipla we hope MAC will be a major factor in fight against Covid-19 to prevent disease from progressing to further severity”.
The Trump fame monoclonal antibody therapy has been givenapproval in India recently. The first person to be administered this therapy was an 84-year-old male COVID positive patient and was saved. This therapy came into limelight after former president used this therapy and flaunted its efficacy. It is an FDA approved therapy demonstrating good efficacy in phase ½ and phase 3 studies by reducing COVID 19 related hospitalization and death by 70 percent. The introduction of this therapy has brought about a paradigm shift in Corona Virus treatment in India.
%20raises%20hopes%20of%20Effective%20Regulation%20&%20Patient%20Safety){kind=link}
